Advertisement

Usefulness of Aspirin for Primary Prevention of Atherosclerotic Cardiovascular Disease

Published:September 09, 2019DOI:https://doi.org/10.1016/j.amjcard.2019.08.040
      Aspirin use in the prevention of cardiovascular events has been a mainstay of treatment for decades. However, the use of aspirin in primary prevention of atherosclerotic cardiovascular disease has recently come under scrutiny. Several recent studies have evaluated the use of aspirin in primary prevention and the results suggest that in many patients the risks may outweigh the benefits. Closer examination of these trials suggests that the use of aspirin therapy for primary prevention may have a role but likely needs a more tailored approach and that caution is needed in prescribing aspirin for primary prevention. In conclusion, in this article we review the evolving evidence for aspirin in the primary prevention of atherosclerotic cardiovascular disease.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Jack D.
        One hundred years of aspirin.
        Lancet. 1997; 350: 437-439
        • Craven L.
        Coronary thrombosis can be prevented.
        J Insur Med. 1950; 5: 47-48
        • Warner T
        • Nylander S
        • Whatling C
        Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy.
        Br J Clin Pharmacol. 2011; 72: 619-633
      1. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
        Lancet. 1988; 2: 349-360
        • Antithrombotic Trialists Collaboration
        Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
        BMJ. 2002; 324: 71-86
        • Goff D
        • Lloyd-Jones D
        • Bennett G
        • Coady S
        • D'Agostino RB
        • Gibbons R
        • Greenland P
        • Lackland D
        • Levy D
        • O'Donnell C
        • Robinson J
        • Schwartz J
        • Shero S
        • Smith S
        • Sorlie P
        • Stone N
        • Wilson P
        2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
        Circulation. 2014; 129: S49-S73
        • Lloyd-Jones D
        • Braun L
        • Ndumele C
        • Smith S
        • Sperling L
        • Virani S
        • Blumenthal R
        Use of risk assessment tools to guide decision-making in the primary prevention of atherosclerotic cardiovascular disease: a special report from the American Heart Association and American College of Cardiology.
        J Am Coll Cardiol. 2018; 73: 3153-3167
        • Grundy S
        • Stone N
        • Bailey A
        • Beam C
        • Birtcher K
        • Blumenthal R
        • Braun L
        • de Ferranti S
        • Faiella-Tommasino J
        • Forman D
        • Goldberg R
        • Heidenreich P
        • Hlatky M
        • Jones D
        • Lloyd-Jones D
        • Lopez-Pajares N
        • Ndumele C
        • Orringer C
        • Peralta C
        • Saseen J
        • Smith S
        • Sperling L
        • Virani S
        • Yeboah J
        2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
        J Am Coll Cardiol. 2019; 73: 3168-3209
        • Whelton P
        • Carey R
        • Aronow W
        • Casey D
        • Collins K
        • Dennison Himmelfarb C
        • DePalma S
        • Gidding S
        • Jamerson K
        • Jones D
        • MacLaughlin E
        • Muntner P
        • Ovbiagele B
        • Smith S
        • Spencer C
        • Stafford R
        • Taler S
        • Thomas R
        • Williams K
        • Williamson J
        • Wright J
        2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
        Hypertension. 2018; 71: 1269-1324
        • Mahmoud A
        • Gad
        • Elgendy M
        • Elgendy A
        • Bavry A I
        Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized controlled trials.
        Eur Heart J. 2019; 40: 607-617
        • Steering Committee of the Physicians' Health Study Research G
        Final report on the aspirin component of the ongoing Physicians' Health Study.
        N Engl J Med. 1989; 321: 129-135
        • Ogawa H
        • Nakayama M
        • Morimoto T
        • Uemura S
        • Kanauchi M
        • Doi N
        • Jinnouchi H
        • Sugiyama S
        • Saito Y
        • Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators
        Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.
        JAMA. 2008; 300: 2134-2141
        • Belch J
        • MacCuish A
        • Campbell I
        • Cobbe S
        • Taylor R
        • Prescott R
        • Lee R
        • Bancroft J
        • MacEwan S
        • Shepherd J
        • Macfarlane P
        • Morris A
        • Jung R
        • Kelly C
        • Connacher A
        • Peden N
        • Jamieson A
        • Matthews D
        • Leese G
        • McKnight J
        • O'Brien I
        • Semple C
        • Petrie J
        • Gordon D
        • Pringle S
        • MacWalter R
        • Prevention of Progression of Arterial Disease and Diabetes Study Group
        • Diabetes Registry Group
        • Royal College of Physicians Edinburgh
        The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease.
        BMJ. 2008; 337: a1840
        • Gaziano JM
        • Brotons C
        • Coppolecchia R
        • Cricelli C
        • Darius H
        • Gorelick PB
        • Howard G
        • Pearson T
        • Rothwell P
        • Ruilope L
        • Tendera M
        • Tognoni G
        • ARRIVE Executive Committee
        Use of Aspirin to Reduce Risk of Initial Vascular Events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
        Lancet. 2018; 392: 1036-1046
        • Bowman L
        • Mafham M
        • Wallendszus K
        • Stevens W
        • Buck G
        • Barton J
        • Murphy K
        • Aung T
        • Haynes R
        • Cox J
        • Murawska A
        • Young A
        • Lay M
        • Chen F
        • Sammons E
        • Waters E
        • Adler A
        • Bodansky J
        • Farmer A
        • McPherson R
        • Neil A
        • Simpson D
        • Peto R
        • Baigent C
        • Collins R
        • Parish S
        • Armitage J
        • ASCEND Study Collaborative Group
        Effects of aspirin for primary prevention in persons with diabetes mellitus.
        N Engl J Med. 2018; 379: 1529-1539
        • McNeil J
        • Woods R
        • Nelson M
        • Reid C
        • Kirpach B
        • Wolfe R
        • Storey E
        • Shah R
        • Lockery J
        • Tonkin A
        • Newman A
        • Williamson J
        • Margolis K
        • Ernst M
        • Abhayaratna W
        • Stocks N
        • Fitzgerald S
        • Orchard S
        • Trevaks R
        • Beilin L
        • Donnan G
        • Gibbs P
        • Johnston C
        • Ryan J
        • Radziszewska B
        • Grimm R
        • Murray A
        • ASPREE Investigator Group
        Effect of aspirin on disability-free survival in the healthy elderly.
        N Engl J Med. 2018; 379: 1499-1508
        • Zheng S
        • Roddick A
        Association of aspirin use for primary prevention with cardiovascular events and bleeding events: a systematic review and meta-analysis.
        JAMA. 2019; 321: 277-287
        • Gaziano J.
        Aspirin for primary prevention: clinical considerations in 2019.
        JAMA. 2019; 321: 253-255
        • American College of Cardiology F
        ASCVD Risk Estimator Plus.
        2014
        • Miedema M
        • Duprez D
        • Misialek J
        • Blaha M
        • Nasir K
        • Silverman M
        • Blankstein R
        • Budoff M
        • Greenland P
        • Folsom A
        Use of coronary artery calcium testing to guide aspirin utilization for primary prevention: estimates from the multi-ethnic study of atherosclerosis.
        Circ Cardiovasc Qual Outcomes. 2014; 7: 453-460
        • Piepoli M
        • Hoes A
        • Agewall S
        • Albus C
        • Brotons C
        • Catapano A
        • Cooney M
        • Corrà U
        • Cosyns B
        • Deaton C
        • Graham I
        • Hall M
        • Hobbs F
        • Løchen M
        • Löllgen H
        • Marques-Vidal P
        • Perk J
        • Prescott E
        • Redon J
        • Richter D
        • Sattar N
        • Smulders Y
        • Tiberi M
        • van der Worp H
        • van Dis I
        • Verschuren W
        • Binno S
        • ESC Scientific Document Group
        2016 European guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR).
        Eur Heart J. 2016; 37: 2315-2381
        • Martin S
        • Sperling L
        • Blaha M
        • Wilson P
        • Gluckman T
        • Blumenthal R
        • Stone N
        Clinician-patient risk discussion for atherosclerotic cardiovascular disease prevention: importance to implementation of the 2013 ACC/AHA guidelines.
        J Am Coll Cardiol. 2015; 65: 1361-1368
        • Ridker P.
        Should aspirin be used for primary prevention in the post-statin era?.
        N Engl J Med. 2018; 379: 1572-1574
        • Mora S
        • Manson J
        Aspirin for primary prevention of atherosclerotic cardiovascular disease: advances in diagnosis and treatment.
        JAMA Intern Med. 2016; 176: 1195-1204